On enrolment, all the patients were already on some form of treatment for heart failure; 38 (88.4%) were on diuretics, 28 (65.1%) were on angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and 26 (60.5%) were on spironolactone. Here, ACE is linked to heart failure.